Sorbonne University

MaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Mardi, novembre 9, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Society, Phase, Cancer, Biomarker, Graft-versus-host disease, MET, Degenerative disease, Hospital, CGMP, ASH, Sorbonne University, Euronext Paris, Enema, EAP, Treatment, Immune reconstitution inflammatory syndrome, GI, Company, Survival, Patient, Head, Pharmaceutical industry

The HERACLES results include data from 24 patients with grade III-IV, steroid-resistant, gastrointestinal (GI)-predominant, acute Graft-versus-Host-Disease (aGvHD) that were treated with MaaT013 as second line therapy.

Key Points: 
  • The HERACLES results include data from 24 patients with grade III-IV, steroid-resistant, gastrointestinal (GI)-predominant, acute Graft-versus-Host-Disease (aGvHD) that were treated with MaaT013 as second line therapy.
  • MaaT013 is a high-richness, high-diversity Microbiome Ecosystem Therapy (MET) derived from pooled donations from strictly vetted healthy individuals and is presented as an enema.
  • Title: Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program
    Session Name: 722.
  • MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology.

PathMaker Neurosystems Announces Completion of Pivotal European Clinical Trial Evaluating MyoRegulator® for the Non-Invasive Treatment of Post-Stroke Spasticity

Retrieved on: 
Lundi, septembre 27, 2021
Clinical trial, MTS, Stroke, Queensland Brain Institute, Health, Amyotrophic lateral sclerosis, FDA, IRB, Institute, Spasticity, Patient, APHP, NSR, Disability, Connective tissue disease, Station F, Heart, GLOBE, US Foods, Food and Drug Administration, Cerebral palsy, CNRS, Neurotoxin, Multiple sclerosis, ALS, Brain, ICM, Safety, INSERM, Traumatic brain injury, Sorbonne University, Lists of diseases, Pharmaceutical industry, Medical device

This clinical trial was conducted at the Paris Brain Institute (ICM) in the Piti-Salptrire Hospital in Paris, France and was sponsored by INSERM.

Key Points: 
  • This clinical trial was conducted at the Paris Brain Institute (ICM) in the Piti-Salptrire Hospital in Paris, France and was sponsored by INSERM.
  • We are pleased to have completed this clinical trial to evaluate our MyoRegulator device, commented Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker.
  • Completion of this trial is an important step in advancing this product as a novel approach to the treatment of spasticity that does not require injected neurotoxins or sedating pharmaceuticals.
  • MyoRegulator will be the worlds first non-invasive neuromodulation device for the treatment for muscle spasticity, and will enable the treatment of patients without the need for drugs or surgery.

Biophytis Reports H1 2021 Financial Results and Provides Business Update

Retrieved on: 
Vendredi, septembre 17, 2021
Board, Risk, ADSS, Medical Affairs Bureau, Patient, U.S. Securities and Exchange Commission, AE, CDMO, Ageing, Contract, CMO, Failure rate, Research, State Administrative Expenses, Program, Ticker, Forward-looking statement, IPO, Astellas Pharma, DMD, Sorbonne University, EMA, Judgement, Annual report, Therapy, COVID-19, Degenerative disease, Data monitoring committee, FFPM, Security (finance), FDA, ADS, SARA, Atlas, Phase, Safety, MBA, Statutory auditor, SEC, Euronext Growth, DMC, Novartis, Duchenne muscular dystrophy, Trial of the century, Company, Conditional, Clinical trial, Review, Interim, American depositary receipt, Mission statement, Audit, Dietary supplement, Pharmaceutical industry, Management, Cryptocurrency

On August 2, 2021, Biophytis announced top line results of the SARA-INT phase 2 clinical study with Sarconeos (BIO101) in Sarcopenia.

Key Points: 
  • On August 2, 2021, Biophytis announced top line results of the SARA-INT phase 2 clinical study with Sarconeos (BIO101) in Sarcopenia.
  • This is a key milestone for Biophytis after 15 years of research and development with Sorbonne University.
  • On June 18, 2021, Biophytis announced a new ORNANE contract with Atlas Capital for 32 million (the "2021 Atlas Contract").
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis.

Spikimm and Institut Pasteur Announce That SPKM001, A Next-generation, Highly Potent Anti-SARS-CoV-2 Human Monoclonal Antibody, Effectively Neutralizes the Delta and Delta Plus Variants

Retrieved on: 
Mercredi, septembre 8, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Other Health, SpikImm, Truffle Capital, the Institut Pasteur and Pasteur Network, SPIKIMM, TRUFFLE CAPITAL, THE INSTITUT PASTEUR AND PASTEUR NETWORK

SPKM001 is a high affinity human monoclonal antibody which targets the receptor-binding site (RBD) on the SARS-CoV-2 Spike protein.

Key Points: 
  • SPKM001 is a high affinity human monoclonal antibody which targets the receptor-binding site (RBD) on the SARS-CoV-2 Spike protein.
  • SpikImm has recently signed an exclusive worldwide license agreement with the Institut Pasteur for the development of anti-SARS-CoV-2 (Covid-19) monoclonal antibodies (mAbs), including SPKM001.
  • Delta Plus, which the World Health Organization also lists as a variant of concern, was first detected in the U.K. in June.
  • It has since been found in several other countries, including the U.S., India, China, Russia, and Japan.

Noema Pharma Initiates Phase 2a Allevia Study of PDE10A Inhibitor NOE-105 in Tourette Syndrome

Retrieved on: 
Jeudi, août 5, 2021
Royal Melbourne Hospital, Clinical trial, Trigeminal neuralgia, Tuberous sclerosis complex tumor suppressors, Sorbonne University, Hospital, Brain, Insulin resistance, Seizure, Patient, Male, CNS, Glutamate (neurotransmitter), Tic, Neuron, PET, Sofinnova, TSC, Adult, Institute, PDE10A, Safety, Neurodevelopmental disorder, Blinking, GLOBE, Pharmaceutical industry

BASEL, Switzerland, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the initiation of its first clinical trial, a Phase 2a dose ranging study of the PDE10A inhibitor NOE-105 in Tourette Syndrome.

Key Points: 
  • BASEL, Switzerland, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the initiation of its first clinical trial, a Phase 2a dose ranging study of the PDE10A inhibitor NOE-105 in Tourette Syndrome.
  • This dose ranging study will help generate useful data to understand the efficacy and safety of NOE-105 in patients with Tourette Syndrome, said Dr George Garibaldi, Chief Medical Officer of Noema Pharma.
  • Dr Andreas Hartmann said: Tourette Syndrome can be a devastating disease, significantly affecting patients confidence and ability to go about everyday tasks.
  • NOE-105, a PDE10A inhibitor, is in Phase 2 for the treatment of Tourette Syndrome.